158 related articles for article (PubMed ID: 38182995)
1. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
Zhang R; Chen Y; Liu X; Gui X; Zhu A; Jiang H; Shao B; Liang X; Yan Y; Zhang J; Song G; Li H
Front Oncol; 2023; 13():1076469. PubMed ID: 37397355
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study.
Fan W; Ding J; Zhong W
Tohoku J Exp Med; 2023 May; 260(1):13-20. PubMed ID: 36696982
[TBL] [Abstract][Full Text] [Related]
7. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
8. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients].
Ou KP; Li Q; Luo Y; Lyu JJ; Zhou H; Yang Y; Cai YJ; Wang ZJ; Wang X; Qi LQ; Ma F; Xu BH
Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):966-971. PubMed ID: 33256310
[No Abstract] [Full Text] [Related]
11. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
12. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases.
Chen X; Bai X; Xie X; Huang J; Chen L; Song L; Lan X; Zhang Q; Guo J; Du C
Ann Med; 2023 Dec; 55(1):2218647. PubMed ID: 37260331
[TBL] [Abstract][Full Text] [Related]
14. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
Leng J; Li DR; Huang LM; Ji XH; Wang DL
Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
[TBL] [Abstract][Full Text] [Related]
15. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.
Li DD; Tao ZH; Wang BY; Wang LP; Cao J; Hu XC; Zhang J
NPJ Breast Cancer; 2022 Sep; 8(1):110. PubMed ID: 36127351
[TBL] [Abstract][Full Text] [Related]
16. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
Wu S; Zhang L; Li H; Xu J; Jiang C; Sun T
Trials; 2020 May; 21(1):420. PubMed ID: 32448335
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
18. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
20. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
Cao M; Lu H; Yan S; Pang H; Sun L; Li C; Chen X; Liu W; Hu J; Huang J; Xing Y; Zhang N; Chen Y; He T; Zhao D; Sun Y; Zhao L; Liu X; Cai L
BMC Cancer; 2023 May; 23(1):463. PubMed ID: 37208633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
